Status: IPO (NASDAQ: ARVN)

 

Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins. Targeted at people living with cancers and other difficult-to-treat diseases, their proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.

 

Arvinas was listed on NASDAQ in 2018.

 

To learn more, please visit: www.arvinas.com